Literature DB >> 35068792

Prevalence, Predictors, and Outcomes of Esophageal Candidiasis in Cirrhosis: An Observational Study With Systematic Review and Meta-Analysis (CANDID-VIEW).

Nipun Verma1, Saurabh Mishra1, Shreya Singh2, Arka De1, Madhumita Premkumar1, Sunil Taneja1, Ajay Duseja1, Virendra Singh1.   

Abstract

BACKGROUND: Gastrointestinal candidiasis is often neglected and potentially serious infection in cirrhosis patients. Therefore, we evaluated the prevalence, risk factors, and outcomes of esophageal candidiasis (EC) in cirrhotics and did a systematic review to summarize EC's available evidence in cirrhosis.
METHODS: Consecutive patients with cirrhosis posted for esophagogastroduodenoscopy (EGD) at a tertiary care institute were screened for EC (cases) between January 2019 and March 2020. EC was diagnosed on EGD findings and/or brush cytology. Controls (without EC) were recruited randomly, and EC's risk factors and outcomes were compared between cases and controls.Four electronic databases were searched for studies describing EC in cirrhosis. Prevalence estimates of EC were pooled on random-effects meta-analysis, and heterogeneity was assessed by I2. A checklist for prevalence studies was used to evaluate the risk of bias in studies.
RESULTS: EC was diagnosed in 100 of 2762 patients with cirrhosis (3.6%). Patients with EC had a higher model for end-stage liver disease (MELD) (12.4 vs. 11.2; P = 0.007), acute-on-chronic liver failure (ACLF) (26% vs. 10%; P = 0.003) and concomitant bacterial infections (24% vs. 7%; P = 0.001), as compared with controls. A multivariable model, including recent alcohol binge, hepatocellular carcinoma (HCC), upper gastrointestinal (UGI) bleed, ACLF, diabetes, and MELD, predicted EC's development in cirrhosis with excellent discrimination (C-index: 0.918). Six percent of cases developed the invasive disease and worsened with multiorgan failures, and four patients with EC died on follow-up.Of 236 articles identified, EC's pooled prevalence from 8 studies (all with low-risk of bias) was 2.1% (95% CI: 0.8-5.8). Risk factors and outcomes of EC in cirrhosis were not reported in the literature.
CONCLUSIONS: EC is not a rare infection in cirrhosis patients, and it may predispose to invasive candidiasis and untimely deaths. Alcohol binge, HCC, UGI bleed, ACLF, diabetes, and higher MELD are the independent predictors of EC in cirrhosis. At-risk patients with cirrhosis or those with deglutition symptoms should be rapidly screened and treated for EC.
© 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V.

Entities:  

Keywords:  ACLF; ACLF, Acute-on-chronic liver failure; AIC, Akaike's Information Criteria; AIDS, Acquired Immunodeficiency Syndrome; BIC, Bayesian Information Criteria; Candida; DM, Diabetes Mellitus; EC, Esophageal Candidiasis; EGD, Esophagogastroduodenoscopy; EVL, Endoscopic Variceal Ligation; HAART, Highly Active Anti-Retroviral Therapy; HCC, Hepatocellular Carcinoma; HIV, Human Immunodeficiency Virus; IC, Invasive Candidiasis; MELD, Model for End-stage Liver Disease; MELD-Na, Model for End-stage Liver Disease-Sodium; RRT, Renal Replacement Therapy; SBP, Spontaneous Bacterial Peritonitis; SIRS, Systemic Inflammatory Response Syndrome; UGI, Upper Gastrointestinal; cirrhosis; esophagitis; invasive fungal infections

Year:  2021        PMID: 35068792      PMCID: PMC8766531          DOI: 10.1016/j.jceh.2021.03.005

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  35 in total

1.  Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement.

Authors:  Damian Hoy; Peter Brooks; Anthony Woolf; Fiona Blyth; Lyn March; Chris Bain; Peter Baker; Emma Smith; Rachelle Buchbinder
Journal:  J Clin Epidemiol       Date:  2012-06-27       Impact factor: 6.437

2.  Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.

Authors:  Guadalupe Garcia-Tsao; Juan G Abraldes; Annalisa Berzigotti; Jaime Bosch
Journal:  Hepatology       Date:  2016-12-01       Impact factor: 17.425

3.  Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; K Rajender Reddy; Florence Wong; Jody C Olson; Ram M Subramanian; Geri Brown; Nicole A Noble; Leroy R Thacker; Patrick S Kamath
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

Review 4.  Infections complicating cirrhosis.

Authors:  Salvatore Piano; Alessandra Brocca; Sara Mareso; Paolo Angeli
Journal:  Liver Int       Date:  2018-02       Impact factor: 5.828

5.  Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.

Authors:  Salvatore Piano; Virendra Singh; Paolo Caraceni; Rakhi Maiwall; Carlo Alessandria; Javier Fernandez; Elza Cotrim Soares; Dong Joon Kim; Sung Eun Kim; Monica Marino; Julio Vorobioff; Rita de Cassia Ribeiro Barea; Manuela Merli; Laure Elkrief; Victor Vargas; Aleksander Krag; Shivaram Prasad Singh; Laurentius Adrianto Lesmana; Claudio Toledo; Sebastian Marciano; Xavier Verhelst; Florence Wong; Nicolas Intagliata; Liane Rabinowich; Luis Colombato; Sang Gyune Kim; Alexander Gerbes; Francois Durand; Juan Pablo Roblero; Kalyan Ram Bhamidimarri; Thomas D Boyer; Marina Maevskaya; Eduardo Fassio; Hyoung Su Kim; Jae Seok Hwang; Pere Gines; Adrian Gadano; Shiv Kumar Sarin; Paolo Angeli
Journal:  Gastroenterology       Date:  2018-12-13       Impact factor: 22.682

6.  Fungal colonization of the esophagus in alcoholic liver disease.

Authors:  Z Péter; J Zala; O Szabó; L Telegdy; Z Horváth; M Makara; J Schuller
Journal:  Z Gastroenterol       Date:  2000-10       Impact factor: 2.000

7.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

Authors:  Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

Review 8.  Diagnosis and Treatment of Esophageal Candidiasis: Current Updates.

Authors:  Abdimajid Ahmed Mohamed; Xin-Liang Lu; Faycal Awaleh Mounmin
Journal:  Can J Gastroenterol Hepatol       Date:  2019-10-20

9.  Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study.

Authors:  Rajiv Jalan; Vanessa Stadlbauer; Sambit Sen; Lisa Cheshire; Yu-Mei Chang; Rajeshwar P Mookerjee
Journal:  Crit Care       Date:  2012-11-27       Impact factor: 9.097

10.  Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy.

Authors:  So Nishimura; Naoyoshi Nagata; Takuro Shimbo; Naoki Asayama; Junichi Akiyama; Norio Ohmagari; Hirohisa Yazaki; Shinichi Oka; Naomi Uemura
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.